-3.05% for Abbott Laboratories stock as persistent selling outweighs support

Traders Union
All News
Financial News
Abbott Laboratories slides 3.05% today

Highlights

Abbott Laboratories announced a $0.63 per share dividend and issued Q1 2026 guidance of $1.12–$1.18 EPS, with FY 2026 EPS forecast at $5.55–$5.80.
Recent developments include institutional accumulation by Prime Capital and new precision oncology integration with Flatiron Health’s OncoEMR platform.
Shares trade under strong bearish momentum with persistent selling, projected to remain in the $97.00–$102.00 range over the next week barring a breakout above $107.40.

Dividend declaration and new partnerships as selling persists

Abbott Laboratories declared a dividend payment of $0.63 per share for investors of record on April 15, 2026, with the ex-dividend date also set for April 15. The company provided Q1 2026 earnings guidance between $1.120 and $1.180 per share and FY 2026 guidance at $5.550–$5.800 EPS, with first quarter results scheduled for release on April 16. Additional recent developments included a substantial increase in shares held by Prime Capital Investment Advisors LLC and the integration of Abbott’s Precision Oncology test portfolio into Flatiron Health’s OncoEMR platform, though price action has remained under broader selling pressure.

Bearish momentum confirmed by oversold signals and strong resistance

Technically, robust selling momentum is confirmed as ABT trades well below its key moving averages, with the Ichimoku Kijun at $107.42 acting as immediate resistance. MACD and ADX on both daily and weekly timeframes maintain bearish momentum; RSI and CCI sit in clear sell territory, while stoch RSI and BBP reflect oversold conditions and pronounced seller dominance intraday. The absence of any significant gap at the open, with the price near session lows, further highlights strong volatility and entrenched downside pressure.

Downside risk elevated as volatility bands tighten below resistance

Over the next five trading days, ABT is likely to fluctuate within a $97.00 – $102.00 volatility band relative to current levels. The probability of a further price decrease is estimated above 80%, with a sideways movement in the lower range as the baseline scenario. A bullish reversal would require a decisive move above the $107.40 resistance, while a break below $97.00 could trigger accelerated selling and further downside.

Viktoras Karapetjanc, expert at Traders Union, sees Abbott Laboratories as fundamentally resilient but currently pressured by negative sentiment and technical weakness. He believes institutional interest and new product partnerships signal underlying strength, yet the strong macro downtrend is hard to ignore. Karapetjanc expects continued volatility, with a higher likelihood of consolidation near current lows, unless the $107.40 resistance is reclaimed. "The long-term story is intact, but for now, patience and watching for a confirmed reversal above $107.40 is my tactical preference."

Earlier, analysts noted that Abbott Laboratories was experiencing sustained bearish momentum and persistent downside pressure according to technical indicators. The current market action reinforces this outlook, and with a break below the $97.00 level likely to prompt accelerated selling, investors should closely monitor for further downside risk in the coming sessions.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.